These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34656301)

  • 1. [Germline testing for patients with metastatic and localized high-risk prostate cancer: Towards a widespread use?].
    Marchand-Créty C
    Bull Cancer; 2021 Nov; 108(11):994-998. PubMed ID: 34656301
    [No Abstract]   [Full Text] [Related]  

  • 2. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL; Szymaniak BM; Numan Y; Morgans AK
    Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
    Wilkens EP; Freije D; Xu J; Nusskern DR; Suzuki H; Isaacs SD; Wiley K; Bujnovsky P; Meyers DA; Walsh PC; Isaacs WB
    Prostate; 1999 Jun; 39(4):280-4. PubMed ID: 10344217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
    Manguoğlu E; Güran S; Yamaç D; Colak T; Simşek M; Baykara M; Akaydın M; Lüleci G
    Cancer Genet Cytogenet; 2010 Dec; 203(2):230-7. PubMed ID: 21156238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
    Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
    Pritchard CC
    Can J Urol; 2019 Oct; 26(5 Suppl 2):24-26. PubMed ID: 31629422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline and somatic DNA repair gene alterations in prostate cancer.
    Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
    Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-cancer screening targets men with BRCA mutations.
    Bonn D
    Lancet Oncol; 2002 Dec; 3(12):714. PubMed ID: 12473505
    [No Abstract]   [Full Text] [Related]  

  • 17. A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes.
    Caldes T; de la Hoya M; Tosar A; Sulleiro S; Godino J; Ibañez D; Martin M; Perez-Segura P; Diaz-Rubio E
    J Med Genet; 2002 Aug; 39(8):e44. PubMed ID: 12161611
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 19. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.